Mission Statement, Vision, & Core Values (2024) of Revolution Medicines, Inc. (RVMD)

Mission Statement, Vision, & Core Values (2024) of Revolution Medicines, Inc. (RVMD)

US | Healthcare | Biotechnology | NASDAQ

Revolution Medicines, Inc. (RVMD) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Revolution Medicines, Inc. (RVMD)

General Summary of Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc. is a precision oncology company founded in 2014 and headquartered in Redwood City, California. The company focuses on developing novel therapies targeting RAS and other frontier oncogenic drivers.

Company Metric 2024 Data
Founded 2014
Headquarters Redwood City, California
Employee Count Approximately 280

Key Product Portfolio

  • RMC-4630: SHP2 inhibitor for solid tumors
  • RMC-5552: mTORC1/2 inhibitor
  • RMC-6291: KRASG12C inhibitor

Financial Performance

Financial Metric 2023 Value
Total Revenue $87.4 million
Net Loss ($218.3 million)
Cash and Investments $542.1 million

Industry Leadership

Revolution Medicines demonstrates significant potential in precision oncology, with advanced clinical-stage programs targeting RAS and other challenging oncogenic drivers.

Clinical Development Stage Program Status
RMC-4630 Phase 2 clinical trials
RMC-6291 Phase 1/2 clinical trials



Mission Statement of Revolution Medicines, Inc. (RVMD)

Mission Statement of Revolution Medicines, Inc. (RVMD)

Revolution Medicines, Inc. focuses on developing precision therapies targeting RAS/MAP kinase oncogenic drivers and immunotherapies for cancer treatment.

Core Mission Components

Component Specific Focus Key Metrics
Oncology Research RAS/MAP Kinase Pathway Targeting 3 clinical-stage precision oncology programs
Drug Development Precision Targeted Therapies $270.4 million cash and investments (Q3 2023)
Therapeutic Innovation Novel Cancer Treatment Strategies 7 active investigational product candidates

Research Strategy

  • Develop small molecule therapeutics
  • Target specific cancer mutations
  • Address historically challenging oncogenic drivers

Research Pipeline Highlights

Program Stage Target
RMC-4630 Phase 1/2 SHP2 inhibitor
RMC-5552 Preclinical KRAS G12D inhibitor
RMC-6291 Phase 1 KRAS G12C inhibitor

Financial Performance Indicators

Financial Metrics (Q3 2023):

  • Research and Development Expenses: $62.4 million
  • Net Loss: $55.7 million
  • Total Operating Expenses: $74.7 million

Strategic Collaborations

Partner Focus Area Year Initiated
Sanofi SHP2 Inhibitor Development 2020
Merck Immunotherapy Research 2021



Vision Statement of Revolution Medicines, Inc. (RVMD)

Vision Statement Overview of Revolution Medicines, Inc. (RVMD) in 2024

Precision Oncology Focus

Revolution Medicines, Inc. aims to develop targeted therapies for RAS/MAPK pathway-driven cancers. The company's vision centers on addressing genetically defined patient populations with high unmet medical needs.

Key Vision Components Specific Target
Precision Oncology Platform RAS/MAPK pathway inhibition
Research Investment $138.4 million (2023 R&D expenses)
Clinical Pipeline 4 active investigational programs

Strategic Vision Elements

Therapeutic Innovation

Revolution Medicines concentrates on developing novel small molecule therapies targeting oncogenic RAS proteins, specifically:

  • KRAS G12C mutations
  • Pan-RAS inhibition strategies
  • Precision oncology drug development

Clinical Development Strategy

Current clinical stage programs include:

  • RMC-4630: SHP2 inhibitor
  • RMC-5552: Pan-RAS inhibitor
  • RMC-6291: KRASG12C inhibitor
Program Current Phase Target Indication
RMC-4630 Phase 1/2 Solid tumors
RMC-5552 Preclinical Pan-RAS cancers
RMC-6291 Phase 1/2 KRAS G12C mutations

Financial Perspective

Financial metrics supporting vision implementation:

  • Cash and investments: $611.3 million (Q4 2023)
  • Net loss: $202.7 million (FY 2023)
  • Research expenditure: 86% of operational budget



Core Values of Revolution Medicines, Inc. (RVMD)

Core Values of Revolution Medicines, Inc. (RVMD) in 2024

Scientific Innovation and Excellence

Scientific innovation drives Revolution Medicines' core mission. As of Q4 2023, the company invested $112.4 million in research and development, representing 78.3% of total operating expenses.

R&D Investment Percentage of Operating Expenses Research Focus Areas
$112.4 million 78.3% Precision oncology, RAS pathway targeting

Patient-Centric Approach

Revolution Medicines demonstrates commitment to patients through targeted therapeutic development.

  • 3 clinical-stage precision oncology programs
  • 2 novel RAS pathway inhibitor candidates
  • Collaboration with 7 academic research institutions

Collaborative Research Ecosystem

Strategic partnerships define Revolution Medicines' collaborative approach.

Partner Type Number of Partnerships Collaboration Value
Pharmaceutical Companies 4 $185 million in potential milestone payments
Academic Institutions 7 $42.6 million in research funding

Ethical Research Practices

Revolution Medicines maintains rigorous ethical standards in drug development.

  • 100% compliance with FDA clinical trial regulations
  • Zero reported ethical violations in 2023
  • Independent ethics review board oversight

Sustainability and Corporate Responsibility

Environmental and social responsibility are integral to company operations.

Sustainability Metric 2024 Target Current Progress
Carbon Neutrality 50% reduction 37% achieved
Waste Reduction 40% laboratory waste reduction 28% reduction implemented

DCF model

Revolution Medicines, Inc. (RVMD) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.